{"organizations": [], "uuid": "c6f791cccc3f3b70111789753748328e7212838c", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180306.html", "section_title": "Archive News &amp; Video for Tuesday, 06 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-citius-reports-progress-in-hemorro/brief-citius-reports-progress-in-hemorroid-treatment-program-idUSFWN1QO0DV", "country": "US", "domain_rank": 408, "title": "BRIEF-Citius Reports Progress In Hemorroid Treatment Program", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.913, "site_type": "news", "published": "2018-03-06T21:24:00.000+02:00", "replies_count": 0, "uuid": "c6f791cccc3f3b70111789753748328e7212838c"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-citius-reports-progress-in-hemorro/brief-citius-reports-progress-in-hemorroid-treatment-program-idUSFWN1QO0DV", "ord_in_thread": 0, "title": "BRIEF-Citius Reports Progress In Hemorroid Treatment Program", "locations": [], "entities": {"persons": [], "locations": [{"name": "new formulation", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "citius pharmaceuticals inc", "sentiment": "negative"}, {"name": "fda", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 6 (Reuters) - Citius Pharmaceuticals Inc:\n* CITIUS REPORTS PROGRESS IN HEMORROID TREATMENT PROGRAM * CITIUS PHARMACEUTICALS - SELECTING HIGHER POTENCY CORTICOSTEROID IN ITS STEROID/ANESTHETIC TOPICAL FORMULATION PROGRAM FOR TREATMENT OF HEMORRHOIDS\n* CITIUS PHARMACEUTICALS INC - NEW FORMULATION, CITI-002, WILL COMBINE LIDOCAINE WITH HIGHER POTENCY CORTICOSTEROID\n* CITIUS PHARMACEUTICALS INC - HELD A TYPE C MEETING WITH FDA TO DISCUSS RESULTS OF PHASE 2A STUDY\n* CITIUS PHARMACEUTICALS - MEETING WITH FDA ALSO TO OBTAIN ITS VIEW ON PLANS TO SUPPORT POTENTIAL FORMULATION CHANGE FOR PLANNED PHASE 2B STUDY\n* CITIUS PHARMACEUTICALS INC - REQUESTED FDAâ€™S FEEDBACK ON PHASE 2B STUDY DESIGN\n* CITIUS PHARMACEUTICALS - PRE-CLINICAL, CLINICAL DEVELOPMENT PROGRAMS FOR CITI-002 PLANNED TO BE SIMILAR TO THOSE OF CITI-001 Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-03-06T21:24:00.000+02:00", "crawled": "2018-03-07T19:45:48.004+02:00", "highlightTitle": ""}